The Discovery and Patent Acquisition of a New Hair Growth SubstanceWarrantee Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Yusuke Shono,hereinafter referred to as "Warrantee"),(NASDAQ:WRNT) and Aragen LifeSciences Pvt Ltd (Headquarters: Hyderabad - 500076, India; CEO: Manni
Kantipudi, hereinafter referred to as "Aragen") are pleased to announce thesuccessful development of a new hair growth active ingredient, "Isopropyl
Dimethyl Norcarboprost" (hereinafter referred to as "this ingredient"),
which acts through a completely different mechanism from existing hair
growth agents. We have obtained a patent in Japan and filed patentapplications in India, China, and Europe. Through our free insurance andfree healthcare models, Warrantee aims to deliver high-value-added hair
growth products to many people.
In recent years, hair issues have become a major concern not only for men
but also for women, with more than 80% of adults reportedly suffering fromthinning or hair loss due to aging. Hair loss is particularly stressful for
women, and there has been a strong demand for safer hair care products
based on hair science. Driven by a desire to support women's beauty andhealth, Warrantee has been conducting research to explore new hair growthseeds to address the concerns of hair thinning. This research was inspiredby the discovery that certain compounds among prostaglandins have hair
growth-promoting effects.
Focusing on substances with high hair growth-promoting effects, we studied
their molecular structures. The structure of this ingredient is very complex,
and finding a company capable of synthesizing it was challenging. However,
we succeeded by collaborating with Aragen Life Sciences, with expertise inadvanced technologies such as catalyst screening, photo redox andelectrochemistry. Aragen scientists optimized all reaction conditions toachieve high-yield synthesis for this new hair growth active ingredient,"Isopropyl Dimethyl Norcarboprost," making it possible to provide the raw
material at a low cost. In September 2022, we completed patent registration
for this ingredient in Japan, and in April 2024, we completed the transfer ofthese patents to Warrantee. In June 2024, we filed international patents
targeting India, China, and Europe.

Subsequent cell and hair growth model animal tests confirmed the hair
growth activity effect of this prostaglandin-structured ingredient and thesafety of the ingredient itself. The results showed that applying theingredient significantly improved hair thinning in women. Based on theseresearch findings, we successfully developed a hair growth active ingredientcontaining "Isopropyl Dimethyl Norcarboprost."
Effects of Isopropyl Dimethyl Norcarboprost To verify the hair growtheffects of this ingredient, we conducted a hair growth test on rabbits as an
animal experiment at an external specialized institution. In the ingredientapplication group, we created solutions by dissolving this ingredient in two
types of solvents: saline and a solution containing cosmetic minoxidil. In theplacebo application group, we prepared two types of solutions: an equalamount of saline without this ingredient and a solution containing cosmetic
minoxidil, and applied them for 28 days. We measured the rabbits'
eyelashes before sample collection on days 2, 7, 14, 21, and 28 of application.
The comparison between the application group and the placebo group
showed an average of 1.5 times higher hair growth activity in the ingredientapplication group.

A well known hair growth active substance, minoxidil works by dilating thecapillaries around the hair root, delivering more nutrients and oxygen to thehair matrix cells, thereby activating them and promoting hair growth. Incontrast, the physiological activity of compounds with a prostaglandin
structure, including this ingredient, is confirmed to prolong the growthphase of the hair cycle, preventing the transition to the regression phase aslong as the ingredient is applied.

<Not Applied><Applied>

Future Developments We have completed the development of cosmetics
containing this ingredient, and they are expected to be launched on themarket within 3 to 4 months. Regarding the sale of these products, we aim
to generate revenue through our free healthcare model by receiving
advertising fees from sponsors who want to market to people suffering fromhair thinning and providing the products for free for a certain period oramount. Initially, we plan to launch in Japan, but as soon as we securesponsors, we plan to expand globally.

Warrantee also possesses many candidates effective ingredients for various
diseases and health maintenance and intends to collaborate with Aragen,which has technological capabilities, to develop these effective ingredients.
About Warrantee Company
Name: Warrantee Inc.
Headquarters: Otemachi One Tower 6th Floor, 1-2-1 Otemachi, Chiyoda-ku,
Tokyo
Representative: CEO, Yusuke ShonoBusiness: Development and provision of "Free Insurance" and "Free
Healthcare" businesses
URL: https://warrantee.com
Contact: ir@warrantee.co.jp
About Warrantee
Warrantee Inc. is a leading Insurtech and marketing service provider. The
mission of this company is "Connect the world with safety." It aims to createa safer and more comfortable world for everyone by providing insurance andhealthcare services to users free of charge. As part of our "Free Insuranceand Free Healthcare" offering, The company provide technology andinfrastructure to sponsors, end users, and other partners, facilitating
efficient customer relationship building and innovation across variousindustries. The company are opening up our technology and infrastructure
to promote these goals.

Company Name: Aragen Life Sciences Ltd
Location: 28 A, IDA Nacharam Hyderabad - 500076, India
Representative: CEO, Manni Kantipudi
Business: Contract Research, Development and ManufacturingOrganization
URL: https://www.aragen.com
Contact: Sandeep Nair, sandeep.nair@aragen.com

About AragenAragen Life Sciences is a leading R&D and manufacturing solutions
provider to the global life sciences industries. It offers a range of solutions
across the drug development continuum to advance small and largemolecule programs. The Company operates through a global network ofeight sites with a team of ~4200 employees and 450+ PhDs. Its expertiseand experience have enabled over 400 customers (including 6 of the top 10
pharma companies globally) to advance their research programs from early
discovery through development and commercialization. Aragen’s innovativemindset, infrastructure, flexible business models, clear purpose, andproprietary project management platform have enabled it to effectively scaleand service large pharma, biotech, agrochemical, and animal healthindustries globally. Visit www.aragen.com for more details.